Ken Griffin Edgewise Therapeutics, Inc. Put Options Transaction History

Citadel Advisors LLC

8 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	BUY	$15.88 - $29.5 $913,100 - $1.7 Million	57,500 Added 1084.91%	62,800 $1.68 Million
Q2 2024 Aug 14, 2024	SELL	$15.08 - $21.23 $143,260 - $201,685	-9,500 Reduced 64.19%	5,300 $95,000
Q1 2024 May 15, 2024	BUY	$9.25 - $19.97 $75,850 - $163,754	8,200 Added 124.24%	14,800 $269,000
Q4 2023 Feb 14, 2024	BUY	$5.51 - $12.1 $34,713 - $76,230	6,300 Added 2100.0%	6,600 $72,000
Q3 2023 Nov 14, 2023	SELL	$5.73 - $7.69 $9,741 - $13,073	-1,700 Reduced 85.0%	300 $1,000
Q2 2023 Aug 14, 2023	SELL	$5.71 - $10.29 $21,127 - $38,073	-3,700 Reduced 64.91%	2,000 $15,000
Q1 2023 May 15, 2023	BUY	$6.66 - $11.33 $666 - $1,133	100 Added 1.79%	5,700 $38,000
Q4 2022 Feb 14, 2023	BUY	$7.58 - $11.08 $42,448 - $62,048	5,600 New	5,600 $50,000

191

100M

2.17M

410K

Ticker EWTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 63,171,700
Market Cap $1.94B
Description
Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. The Company's lead product candidate, EDG-5506, is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy which has c...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.